Drawing for UBESLO

USPTO serial 99782013

UBESLO

Reviewed by CopyMark Law Group

Status 653
Filing date
Status date
Registration date
—
Examiner
FISHER, DAVID REUBEN
Law office
TMO LAW OFFICE 303

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with UBESLO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michelle Rosenberg

Michelle Rosenberg OUTSIDE GENERAL COUNSEL LLP501 Boylston Street, 10th FloorBoston, MA 02116United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for lowering cholesterol; pharmaceuticals, namely, lipid lowering agents; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and disorders, major adverse cardiac events, cholesterol-related diseases and disorders, dyslipidemia, lipid related diseases and disorders, diabetes, age-related macular degeneration, neurodegenerative diseases and disorders, dementia, Lewy body dementia, and Alzheimer's diseaseACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 31, 2026GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Aug 31, 2026GNSLLETTER OF SUSPENSION E-MAILED—
Aug 31, 2026CNSLSUSPENSION LETTER WRITTEN—
Aug 31, 2026DOCKASSIGNED TO EXAMINER—
Aug 30, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 23, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 23, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance